当前位置:首页 - 行情中心 - 奥翔药业(603229) - 财务分析 - 现金流量表

奥翔药业

(603229)

  

流通市值:92.66亿  总市值:92.66亿
流通股本:8.30亿   总股本:8.30亿

现金流量表

报告期2025-06-302025-03-312024-12-312024-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金411,554,272.5200,368,882.05757,583,630.29529,180,262.28
  收到的税费返还--41,625,214.132,691,412.44
  收到其他与经营活动有关的现金25,108,839.9959,666,816.6354,354,904.4579,924,523.24
  经营活动现金流入小计436,663,112.49260,035,698.68853,563,748.87611,796,197.96
  购买商品、接受劳务支付的现金197,944,336.8791,994,238.05331,550,529.09240,674,729.72
  支付给职工以及为职工支付的现金109,096,442.4765,627,999.79189,341,378.57147,049,464.76
  支付的各项税费33,479,216.210,427,254.1254,712,813.6747,004,365.53
  支付其他与经营活动有关的现金50,739,450.1689,939,819.42100,033,250.1893,164,125.95
  经营活动现金流出的平衡项目-0.01000
  经营活动现金流出小计391,259,445.69257,989,311.38675,637,971.51527,892,685.96
  经营活动产生的现金流量净额45,403,666.82,046,387.3177,925,777.3683,903,512
二、投资活动产生的现金流量:
  取得投资收益收到的现金-5,947,942.72-11,517,089.34
  处置固定资产、无形资产和其他长期资产收回的现金净额282,596.09-39,600-
  收到的其他与投资活动有关的现金39,194,828.99-37,562,444.94-
  投资活动现金流入小计39,477,425.085,947,942.7237,602,044.9411,517,089.34
  购建固定资产、无形资产和其他长期资产支付的现金53,803,090.6934,810,651.22111,302,153.4794,916,998.96
  投资支付的现金2,004,4082,009,8962,249,550.742,249,550.74
  支付其他与投资活动有关的现金11,994,265.02-44,019,277.76-
  投资活动现金流出小计67,801,763.7136,820,547.22157,570,981.9797,166,549.7
  投资活动产生的现金流量净额-28,324,338.63-30,872,604.5-119,968,937.03-85,649,460.36
三、筹资活动产生的现金流量:
  取得借款收到的现金229,390,810.8489,790,810.84270,100,000170,100,000
  收到其他与筹资活动有关的现金17,198,981.95-20,712,726.52-
  筹资活动现金流入小计246,589,792.7989,790,810.84290,812,726.52170,100,000
  偿还债务支付的现金170,100,00070,000,000300,000,000170,000,000
  分配股利、利润或偿付利息支付的现金3,519,572.691,749,440.3384,215,258.6982,175,406.89
  支付其他与筹资活动有关的现金69,114,187.6833,124,760.0214,817,353.395,089,435.18
  筹资活动现金流出小计242,733,760.37104,874,200.35399,032,612.08257,264,842.07
  筹资活动产生的现金流量净额3,856,032.42-15,083,389.51-108,219,885.56-87,164,842.07
四、汇率变动对现金及现金等价物的影响5,776,044.163,875,717.8110,842,676.45-5,520,623.06
五、现金及现金等价物净增加额26,711,404.75-40,033,888.9-39,420,368.78-94,431,413.49
  加:期初现金及现金等价物余额1,048,581,219.151,048,581,219.151,088,001,587.931,088,001,587.93
  期末现金及现金等价物余额1,075,292,623.91,008,547,330.251,048,581,219.15993,570,174.44
补充资料:
  净利润169,346,106.65-206,791,017.22-
  资产减值准备6,415,526.03-9,406,759.08-
  固定资产和投资性房地产折旧33,482,969.78-61,548,139.45-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧33,482,969.78-61,548,139.45-
  无形资产摊销1,113,789.73-2,109,632.65-
  固定资产报废损失--149,775.73-
  公允价值变动损失-545,324.37--5,499,523.61-
  财务费用-1,113,816.55--3,634,494.71-
  投资损失-14,311,078.41--22,864,552.69-
  递延所得税-908,668.17--2,529,615.13-
  其中:递延所得税资产减少-908,668.17--455,987.91-
    递延所得税负债增加---2,073,627.22-
  存货的减少-2,971,305.84--45,590,984.29-
  经营性应收项目的减少-143,441,616.35--23,026,782.45-
  经营性应付项目的增加-1,962,646.21--6,194,577.57-
  现金的期末余额1,075,292,623.9-1,048,581,219.15-
  减:现金的期初余额1,048,581,219.15-1,088,001,587.93-
  现金及现金等价物的净增加额26,711,404.75--39,420,368.78-
公告日期2025-08-292025-04-302025-04-302024-10-30
审计意见(境内)标准无保留意见
TOP↑